Literature DB >> 11756072

Effect of soy protein on endogenous hormones in postmenopausal women.

Victoria W Persky1, Mary E Turyk, Ling Wang, Sally Freels, Robert Chatterton, Stephen Barnes, John Erdman, Daniel W Sepkovic, H Leon Bradlow, Susan Potter.   

Abstract

BACKGROUND: The long-term clinical effects of soy protein containing various concentrations of isoflavones on endogenous hormones are unknown.
OBJECTIVE: We examined the effects of ingestion of soy protein containing various concentrations of isoflavones on hormone values in postmenopausal women.
DESIGN: Seventy-three hypercholesterolemic, free-living, postmenopausal women participated in a 6-mo double-blind trial in which 40 g protein as part of a National Cholesterol Education Program Step I diet was provided as casein from nonfat dry milk (control), isolated soy protein (ISP) containing 56 mg isoflavones (ISP56), or ISP containing 90 mg isoflavones (ISP90). Endogenous hormone concentrations were measured at baseline and at 3 and 6 mo.
RESULTS: The concentration of thyroxine and the free thyroxine index were higher in the ISP56 group, and the concentration of thyroid-stimulating hormone was higher in the ISP90 group than in the control group at 3 and 6 mo (P < 0.05). Triiodothyronine was significantly higher in the ISP90 group only at 6 mo. Thyroxine, free thyroxine index, and thyroid-stimulating hormone at 6 mo were inversely associated with measures of baseline estrogenicity. No significant differences were found for endogenous estrogens, cortisol, dehydroepiandrosterone sulfate, insulin, glucagon, or follicle-stimulating hormone after baseline hormone values were controlled for.
CONCLUSIONS: This study does not provide evidence that long-term ingestion of soy protein alters steroid hormone values, but it suggests that soy protein may have small effects on thyroid hormone values that are unlikely to be clinically important. The thyroid effects are, however, consistent with previous findings in animals and highlight the need for future research investigating possible mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756072     DOI: 10.1093/ajcn/75.1.145

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  19 in total

1.  Equol, via dietary sources or intestinal production, may ameliorate estrogen deficiency-induced bone loss.

Authors:  Connie M Weaver; Leecole L Legette
Journal:  J Nutr       Date:  2010-05-26       Impact factor: 4.798

2.  The estrogenic effect of Pueraria mirifica on gonadotrophin levels in aged monkeys.

Authors:  Hataitip Trisomboon; Suchinda Malaivijitnond; Gen Watanabe; Wichai Cherdshewasart; Kazuyoshi Taya
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 3.  Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation.

Authors:  S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling
Journal:  Arch Toxicol       Date:  2018-08-21       Impact factor: 5.153

Review 4.  Role of phytoestrogens in prevention and management of type 2 diabetes.

Authors:  Mohammad Talaei; An Pan
Journal:  World J Diabetes       Date:  2015-03-15

5.  Effect of soy isoflavones on thyroid hormones in intact and ovariectomized cynomolgus monkeys (Macaca fascicularis).

Authors:  Marnie G Silverstein; Jay R Kaplan; Susan E Appt; Thomas C Register; Carol A Shively
Journal:  Menopause       Date:  2014-10       Impact factor: 2.953

6.  Appetitive hormones, but not isoflavone tablets, influence overall and central adiposity in healthy postmenopausal women.

Authors:  Oksana A Matvienko; D Lee Alekel; Ulrike Genschel; Laura Ritland; Marta D Van Loan; Kenneth J Koehler
Journal:  Menopause       Date:  2010 May-Jun       Impact factor: 2.953

7.  Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women.

Authors:  Francene M Steinberg; Michael J Murray; Richard D Lewis; Margaret A Cramer; Paula Amato; Ronald L Young; Stephen Barnes; Karen L Konzelmann; Joan G Fischer; Kenneth J Ellis; Roman J Shypailo; J Kennard Fraley; E O'Brian Smith; William W Wong
Journal:  Am J Clin Nutr       Date:  2010-12-22       Impact factor: 7.045

8.  Supplemental dietary racemic equol has modest benefits to bone but has mild uterotropic activity in ovariectomized rats.

Authors:  Leecole L Legette; Berdine R Martin; Mohammad Shahnazari; Wang-Hee Lee; William G Helferich; Junqi Qian; David J Waters; Alireza Arabshahi; Stephen Barnes; Jo Welch; David G Bostwick; Connie M Weaver
Journal:  J Nutr       Date:  2009-08-26       Impact factor: 4.798

9.  Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures.

Authors:  Takuya Ohtomo; Mariko Uehara; José Luis Peñalvo; Herman Adlercreutz; Shin-ichi Katsumata; Kazuharu Suzuki; Ken Takeda; Ritsuko Masuyama; Yoshiko Ishimi
Journal:  Eur J Nutr       Date:  2008-07-11       Impact factor: 5.614

10.  Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial.

Authors:  Eva Lydeking-Olsen; Jens-Erik Beck-Jensen; Kenneth D R Setchell; Trine Holm-Jensen
Journal:  Eur J Nutr       Date:  2004-04-14       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.